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Introduction {#humu22946-sec-0010}
============

The histone methyltransferase EZH2 (*enhancer of zeste homolog 2*) (MIM \#601573) is a key epigenetic regulator in mammals. This protein forms the catalytic subunit of the polycomb‐repressive complex 2 (PRC2) \[Kuzmichev et al., [2002](#humu22946-bib-0018){ref-type="ref"}\], and is thought to suppress gene transcription epigenetically by adding up to three methyl groups onto lysine residue 27 of histone H3 (H3K27). Epigenetic silencing via EZH2‐mediated histone methylation is further supported by the fact that some mutations at the level of H3K27 can inhibit the activity of PRC2 \[Lewis et al., [2013](#humu22946-bib-0020){ref-type="ref"}; Pengelly et al., [2013](#humu22946-bib-0030){ref-type="ref"}\].

Somatic mutations of *EZH2* in circulating white blood cells have been shown to be extremely common in hematological malignancies \[Lund et al., [2014](#humu22946-bib-0021){ref-type="ref"}\]. Sequencing of human diffuse large B‐cell and non‐Hodgkin lymphomas revealed recurrent somatic mutations at positions Tyr646, Ala682, and Ala692 (or Tyr641, Ala677, and Ala687 in the shorter EZH2 isoform as referenced in the original publications) \[Morin et al., [2010](#humu22946-bib-0027){ref-type="ref"}; Majer et al., [2012](#humu22946-bib-0022){ref-type="ref"}; McCabe et al., [2012a](#humu22946-bib-0024){ref-type="ref"}\]. The most frequently mutated residue, tyrosine at position 646, has been reported as mutated to phenylalanine (p.Tyr646Phe), asparagine (p.Tyr646Asn), histidine (p.Tyr646His), and serine (p.Tyr646Ser) \[Morin et al., [2010](#humu22946-bib-0027){ref-type="ref"}\]. All of these heterozygous single amino acid substitutions have been shown to change the substrate specificity and favor trimethylation of H3K27 (H3K27me2 →H3K27me3) over monomethylation (H3K27me0→ H3K27me1) and dimethylation (H3K27me1→ H3K27me2). When combined with the activity of the wild‐type (WT) EZH2 copy, which has high affinity for unmethylated H3K27me0 and medium affinity for monomethylated H3K27me1, this results in an overall gain‐of‐function of EZH2 \[Sneeringer et al., [2010](#humu22946-bib-0038){ref-type="ref"}; Yap et al., [2011](#humu22946-bib-0051){ref-type="ref"}\]. Unlike for Tyr646, mutations at the other two sites have only been reported as specific amino acid substitutions, p.Ala682Gly \[McCabe et al., [2012a](#humu22946-bib-0024){ref-type="ref"}\] and p.Ala692Val \[Majer et al., [2012](#humu22946-bib-0022){ref-type="ref"}\].These two alterations also show gain‐of‐function activity but appear to favor different substrates. p.Ala682Gly promotes methyltransferase activity of nearly equal efficiency for all three substrates (H3K27me0/me1/me2), thereby resulting in hypertrimethylation of H3K27 \[McCabe et al., [2012a](#humu22946-bib-0024){ref-type="ref"}\]. By contrast, p,Ala692Val reduces monomethylation and enhances dimethylation of H3K27 while leaving trimethylation virtually unchanged *in vitro* \[Majer et al., [2012](#humu22946-bib-0022){ref-type="ref"}\], although global levels of H3K27me3 were found to be increased in a tumor‐derived p.Ala692Val mutant cell line, or when this mutant was transiently expressed in a cell line with an EZH2 WT background \[Ott et al., [2014](#humu22946-bib-0029){ref-type="ref"}\]. Given that additional data support the increased activity of EZH2 in other cancers, possibly independent of its assembly into the PRC2 complex \[Xu et al., [2012](#humu22946-bib-0050){ref-type="ref"}\], there is intense interest in developing EZH2 inhibitors as potential chemotherapeutic agents \[Knutson et al., [2012](#humu22946-bib-0015){ref-type="ref"}; McCabe et al., [2012b](#humu22946-bib-0025){ref-type="ref"}; Qi et al., [2012](#humu22946-bib-0032){ref-type="ref"}; Knutson et al., 2012; Tan et al., [2014](#humu22946-bib-0040){ref-type="ref"}; Van Aller et al., [2014](#humu22946-bib-0046){ref-type="ref"}\]. Targeting of other proteins in the complex, such as EED and SUZ12, may also become a useful therapeutic strategy \[Tan et al., [2014](#humu22946-bib-0040){ref-type="ref"}\], as may disruption of proper PRC2 complex assembly \[Kim et al., [2013a](#humu22946-bib-0013){ref-type="ref"}\]. Notably, though, inactivating mutations have been found at multiple sites throughout the *EZH2* gene in myeloid disorders and acute lymphoblastic leukemia \[Ernst et al., [2010](#humu22946-bib-0006){ref-type="ref"}; Makishima et al., [2010](#humu22946-bib-0023){ref-type="ref"}; Guglielmelli et al., [2011](#humu22946-bib-0009){ref-type="ref"}; Ntziachristos et al., [2012](#humu22946-bib-0028){ref-type="ref"}; Score et al., [2012](#humu22946-bib-0037){ref-type="ref"}; Zhang et al., [2012](#humu22946-bib-0054){ref-type="ref"}; The Cancer Genome Atlas Research Network, [2013](#humu22946-bib-0044){ref-type="ref"}\], suggesting that some neoplasms may not respond well to EZH2 inhibition.

Recently, we and others have shown that *de novo* germline mutations in *EZH2* cause Weaver syndrome (WS; MIM \#277590), a rare but well‐described developmental disorder of prenatal onset that features intellectual disability, tall stature, macrocephaly, accelerated bone growth and maturation, and a susceptibility to cancers including hematological malignancies \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}; Gibson et al., [2012](#humu22946-bib-0008){ref-type="ref"}; Tatton‐Brown et al., 2013; Tatton‐Brown and Rahman, [2013](#humu22946-bib-0043){ref-type="ref"}\]. Aspects of this phenotype can be explained by the role of Ezh2 in craniofacial skeleton formation \[Schwarz et al., [2014](#humu22946-bib-0036){ref-type="ref"}\]. Though cerebral malformations were not part of the original description of WS \[Weaver et al., [1974](#humu22946-bib-0048){ref-type="ref"}\], recent clinical reports have documented the presence of neuronal migration disorders in association with physical features of WS \[Freeman et al., [1999](#humu22946-bib-0007){ref-type="ref"}; Al‐Salem et al., [2013](#humu22946-bib-0001){ref-type="ref"}; Tatton‐Brown et al., [2013](#humu22946-bib-0042){ref-type="ref"}\]. In the case reported by Al‐Salem et al. ([2013](#humu22946-bib-0001){ref-type="ref"}), polymicrogyria was proven to be associated with a *de novo* mutation in *EZH2*, confirming the diagnosis of WS in this patient. In the more recent case reported by Tatton‐Brown et al. ([2013](#humu22946-bib-0042){ref-type="ref"}), pachy‐ and polymicrogyria were associated with a truncating variant in *EZH2*, classified as likely pathogenic because parental samples were unavailable.

Given that both gain‐of‐function and loss‐of‐function mutations in *EZH2* have been associated with human neoplastic disease when acquired during life in somatic cells \[Ernst et al., [2010](#humu22946-bib-0006){ref-type="ref"}; Yap et al., [2011](#humu22946-bib-0051){ref-type="ref"}; McCabe et al., [2012a](#humu22946-bib-0024){ref-type="ref"}; Ntziachristos et al., [2012](#humu22946-bib-0028){ref-type="ref"}; Lund et al., [2014](#humu22946-bib-0021){ref-type="ref"}\], we hypothesized that germline *de novo* mutations causative of WS would alter EZH2 activity within the PRC2 complex. We further hypothesized that more severe clinical features of WS (such as cerebral migration defects, or the development of leukemia) might be specifically associated with more significant changes in PRC2‐mediated methyltransferase activity conferred by individual mutations in *EZH2*.

Materials and Methods {#humu22946-sec-0020}
=====================

To test our hypothesis, we designed recombinant human EZH2 proteins, had them preassembled into PRC2 complexes (BPS Bioscience, San Diego CA), and tested their activity *in vitro* using a well‐accepted *in vitro* assay \[Ernst et al., [2010](#humu22946-bib-0006){ref-type="ref"}; Yap et al., [2011](#humu22946-bib-0051){ref-type="ref"}; Score et al., [2012](#humu22946-bib-0037){ref-type="ref"}\]. Mutant EZH2--PRC2 complexes were selected for study based on the rare *de novo* variants observed in our original three patients \[Gibson et al., [2012](#humu22946-bib-0008){ref-type="ref"}\] and among other patients with WS identified since. Two other variants that had been observed in patients with both WS and neoplastic disease \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}\] were also selected.

Patients {#humu22946-sec-0030}
--------

Clinical data presented here were collected by the physicians who referred the patients to our study. Participating families provided informed consent, and this study was approved by the joint Clinical Research Ethics Board of the University of British Columbia and British Columbia Children\'s Hospital.

Sequencing {#humu22946-sec-0040}
----------

Sanger sequencing was performed on PCR products from genomic DNA. PCR primers were used to amplify the 19 coding exons of *EZH2* (exons 2--20; primers available upon request) \[Gibson et al., [2012](#humu22946-bib-0008){ref-type="ref"}\]. All primer pairs were confirmed to be specific to the *EZH2* gene on chromosome 7 (NC_000007.13: 148504464--148581441) rather than the pseudogene on chromosome 21 (NC_000021.8: 36971977--36972553) using the BLAST function on NCBI at <http://www.ncbi.nlm.nih.gov//blast/Blast.cgi> (GRCh37.p13 assembly). NCBI Reference sequence NM_004456.4 is available from GenBank. This corresponds to the longest isoform of EZH2. All nomenclature of described sequence variants is based on this sequence and follows the guidelines described in <http://www.hgvs.org/mutnomen/>. Population frequencies for each variant were investigated in the dbSNP database, searchable at <http://www.ncbi.nlm.nih.gov/projects/SNP/>, and the exome variant server, found at <http://evs.gs.washington.edu/EVS/>. Functional predictions for previously undescribed variants were done using the PROVEAN and SIFT tools, available at <http://provean.jcvi.org/index.php> (PROVEAN v1.1.3). Detailed prediction scores are provided in Supp. Table S1. All described pathogenic variants have been submitted to the LOVD locus‐specific database and can be found at <http://www.lovd.nl/EZH2>.

Histone Methyltransferase Assay {#humu22946-sec-0050}
-------------------------------

Core histones were purchased from EMD Millipore (13‐107; Billerica MA) and used as methyl acceptors in most of our *in vitro* reactions. This substrate contains a mix of all core histones and H3 peptides at different methylation states, thereby recapitulating the heterogeneity of endogenous nucleosomes. In an alternative assay, biotinylated peptides (mimicking the H3 tail, H3\[21--44\]) that had been unmethylated (H3K27me0), monomethylated (H3K27me1) or dimethylated (H3K27me2) were used as substrate (Supp. Fig. S1). We purchased PRC2 complexes containing WT EZH2 (51004) or mutant EZH2 from BPS Bioscience \[Morin et al., [2010](#humu22946-bib-0027){ref-type="ref"}\]. Methyltransferase assays were done using a commonly used kit (17--330; EMD Millipore) \[Ernst et al., [2010](#humu22946-bib-0006){ref-type="ref"}; Yap et al., [2011](#humu22946-bib-0051){ref-type="ref"}; Score et al., [2012](#humu22946-bib-0037){ref-type="ref"}\] as per manufacturer\'s instructions. We incubated 250 ng of individual HMTase complexes separately with 0.67 μM ^3^H‐S‐adenosyl‐methionine (^3^H‐SAM) (Perkin Elmer, Waltham MA) and 2 μg core histones (or 1 μM peptide), in 50 mM Tris--HCl, pH 9.0, and 0.5 mM DTT for 30 min at 30°C in a 10 μl volume. Excess volumes of ^3^H‐SAM, core histones, and a longer incubation were also tested (Supp. Fig. S2). In all reactions, five or eight microliters were spotted on a P81 square paper (Millipore), washed (three times with 10% tricholoracetic acid and once with 95% ethanol) to remove unincorporated ^3^H‐Met, air‐dried overnight, placed in a glass scintillation vial with 3 ml of scintillation fluid (ScintiSafe Econo1 SX20‐5 or Scintisafe 30% SX23‐5; Fisher Chemical, Waltham MA), and counted on a 1900TR Liquid Scintillation Analyzer (Perkin Elmer) or LS6500 Multi‐Purpose Scintillation Counter (Beckman Coulter, Brea CA). Normalized counts represent the subtraction of background counts (i.e., control tubes with no enzyme added) from total counts.

Results {#humu22946-sec-0060}
=======

Probands {#humu22946-sec-0070}
--------

Probands 1, 2, and 3 were described previously \[Gibson et al., [2012](#humu22946-bib-0008){ref-type="ref"}\]. The mutations identified in *EZH2* were c.457_459delTAT (p.Tyr153del), c.2080C\>T (p.His694Tyr), and c.394C\>T (p.Pro132Ser), respectively.

Proband 4 was originally published in 2001 \[Huffman et al., [2001](#humu22946-bib-0011){ref-type="ref"}\]. More detailed clinical features are described in Supp. Table S2. Using Sanger sequencing, we identified a c.394C\>T (p.Pro132Ser) mutation in *EZH2*, an alteration previously described in proband 3 from our cohort \[Gibson et al., [2012](#humu22946-bib-0008){ref-type="ref"}\] and not detected in any of the parents of probands 3 or 4. Proband 4 had a stage 4S neuroblastoma, which subsequently underwent spontaneous resolution, as was commonly observed for this type of tumor \[Huffman et al., [2001](#humu22946-bib-0011){ref-type="ref"}\]. At this time, a predisposition for neoplasm development in WS and other overgrowth syndromes was already recognized \[Huffman et al., [2001](#humu22946-bib-0011){ref-type="ref"}\]. This patient also presented with congenital heart defects. Recently, *de novo* mutations in histone‐modifying genes have been implicated in many cases of congenital heart disease \[Zaidi et al., [2013](#humu22946-bib-0053){ref-type="ref"}\], further supporting a role for *EZH2* in this individual\'s phenotype.

The clinical features of proband 5 are summarized in Supp. Table S2. The most striking and unusual feature is polymicrogyria. Photographs and MRI brain images are presented in Figure [1](#humu22946-fig-0001){ref-type="fig"}. A clinical summary is provided in the Supp. Text along with fetal ultrasound results documenting prenatal onset of excessive growth (Supp. Table S3). We identified a c.2050C\>T (p.Arg684Cys) mutation in *EZH2*, confirmed to be *de novo* by trio‐based testing at the BC Children\'s Hospital Clinical Molecular Genetics Lab. This mutation was previously described in four other WS patients \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}\], and thus appears to be a relatively frequent cause of WS.

![Weaver syndrome proband with polymicrogyria described in this study. **A**: Proband 5 is shown at 2, 4, 6, 8, 12, and 19 months. **B**: Both sides of the hand are shown at 12 months to illustrate the prominent palmar crease. **C**: At 27 months, face with prominent rosy cheeks, profile and ears are shown to confirm the dimple is only present behind the right ear. **D**: At 31 months, mild camptodactyly is seen on the toes and a third nipple is apparent. **E**: Full torso and full body are also shown at 31 months. **F**: X‐rays of the hand at 11½ months and the knee at 10½ months are indicative of advanced bone age. **G**: MRI done at 5 days of age illustrates asymmetric perisylvian polymicrogyria.](HUMU-37-301-g001){#humu22946-fig-0001}

The clinical features of probands 6 and 7 are summarized in Supp. Table S2. Further clinical information is provided in the Supp. Text. In both unrelated patients, we identified a c.398A\>G (p.Tyr133Cys) *de novo* mutation in *EZH2*. This mutation was predicted damaging by PROVEAN/SIFT (Supp. Table S1).

We also detected the c.553G\>C (p.Asp185His) variant in *EZH2* in individuals referred to our WS‐like cohort. This variant was predicted damaging by SIFT but not by PROVEAN (Supp. Table S1). Clinical features of carriers of this p.(Asp185His) variant (cases 15, 40, 53, 73, and 95) are summarized in Supp. Table S4 and further clinical information is provided in the Supp. Text. Other members of their families were tested at this locus and in all cases the variant was found to be inherited from one of the parents (Supp. Table S4). p.(Asp185His) is reported in dbSNP (rs2302427C\>G) with minor allele frequencies of 8% in the 1000 Genomes phase 1 population, 6% in the Exome Variant Server, and 7.7% in a healthy ancestrally diverse cohort screened for common variants in cancer‐susceptibility genes \[Bodian et al., [2014](#humu22946-bib-0002){ref-type="ref"}\]. Because of its frequency in the general population, the p.(Asp185His) variant cannot in isolation be causative of WS.

EZH2 Mutations in WS Impair Histone Methyltransferase Activity *In Vitro* {#humu22946-sec-0080}
-------------------------------------------------------------------------

In order to determine the functional impact of the *EZH2* mutations observed in WS, EZH2 mutant proteins corresponding to the mutations observed in WS patients were expressed *in vitro* and then assembled together with other artificially expressed members of the PRC2 complex (EED/SUZ12/RbAp48 and AEBP2). Preassembly into the PRC2 complex was necessary because EZH2 requires other members of PRC2 for activity on nucleosomes \[Kuzmichev et al., [2002](#humu22946-bib-0018){ref-type="ref"}\]. The mutations studied included those identified within our cohort: p.(Tyr153del), p.(His694Tyr), p.(Pro132Ser), p.(Arg684Cys), and p.(Tyr133Cys). The p.(Ala682Thr) and p.(Glu745Lys) mutations were also of interest because of their associations with neuroblastoma, acute lymphoblastic leukemia, and lymphoma in WS patients \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}\]. As mentioned above, we also included the common variant p.(Asp185His). WT EZH2 was used as a positive control, and the methyltransferase‐inactive mutant EZH2 p.(Phe672Ile) (equivalent to the inactive fly mutant allele *E*(*z*)*^son^* ^1^ described in Joshi et al. \[[2008](#humu22946-bib-0012){ref-type="ref"}\]) was used as a negative control. We then measured incorporation of tritiated methyl groups from ^3^H‐SAM onto mixed core histones in the presence of each EZH2‐PRC2 complex (Fig. [2](#humu22946-fig-0002){ref-type="fig"}; Supp. Fig. S3 and Supp. Table S5A). As expected, WT EZH2--PRC2 complex catalyzed the incorporation of ^3^H into core histones, consistent with the model whereby it uses ^3^H‐SAM as the methyl donor and nucleosomes as the recipient substrates for histone methylation \[Kuzmichev et al., [2002](#humu22946-bib-0018){ref-type="ref"}\]. In contrast, PRC2 complexes containing WS‐associated EZH2 mutants showed reduced histone methyltransferase activity *in vitro* (Fig. [2](#humu22946-fig-0002){ref-type="fig"}; Supp. Fig. S3 and Supp. Table S5A), suggesting that *EZH2* mutations associated with WS are loss‐of‐function (hypomorphic) mutations.

![Weaver syndrome mutants are impaired in their histone methyltransferase activity *in vitro*. Histone methyltransferase reactions were performed using 2 μg purified core histones and 0.67 μM ^3^H‐S‐adenosyl‐methionine (^3^H‐SAM). Each reaction was incubated with 250 ng of either wild‐type (WT) or a mutant HMTase complex (or no enzyme controls). Histone methyltransferase activity was measured based on the incorporation of ^3^H‐labeled methyl groups, represented in scintillation counts per minute. Counts were normalized by subtracting background counts (i.e., no enzyme) from the total counts. **A**: Incorporation of tritiated methyl groups from ^3^H‐SAM onto core histones is shown for each complex: EZH2 WT **•**, p.(Phe672Ile) **×**, p.(Pro132Ser) **★**, p.(Tyr153del) △, p.(His694Tyr) ▽, p.(Glu745Lys) ▴, p.(Ala682Thr) ▾, p.(Arg684Cys) ▪, p.(Tyr133Cys) □, and p.(Asp185His) ◇. Error bars represent standard deviation (SD) within the groups "EZH2 WT" and "EZH2 mutants." Unpaired t‐test showed statistically significant difference between the two groups (P value \< 0.0001). **B**: Incorporation of tritiated methyl groups from ^3^H‐SAM onto core histones is shown for the positive control EZH2 WT, the negative control EZH2 (p.Phe672Ile), and the mutant complex with activity closest to WT, namely, EZH2 (p.Pro132Ser). Error bars represent SD of four independent replicates for the controls, and three independent replicates for the mutant EZH2 (p.Pro132Ser). One‐way ANOVA showed statistically significant difference between all groups (overall P value \< 0.0001; P values between WT and p.(Phe672Ile), between p.(Phe672Ile) and p.(Pro132Ser), and between WT and p.(Pro132Ser) were all \<0.05).](HUMU-37-301-g002){#humu22946-fig-0002}

The Common p.(Asp185His) Variant Also Appears to Impair Histone Methyltransferase Activity *In Vitro* {#humu22946-sec-0090}
-----------------------------------------------------------------------------------------------------

Surprisingly, EZH2 p.(Asp185His) also showed impaired histone methyltransferase activity in this *in vitro* assay (Fig. [2](#humu22946-fig-0002){ref-type="fig"}A; Supp. Fig. S3). Based on the frequency of this variant and the rarity of WS, p.(Asp185His) cannot by itself be causative of WS. However, based on the number of replicates we performed under varied conditions (Supp. Fig. S2 and Supp. Tables S5B and C), we believe this result to be reproducible and to reflect accurately the activity of this enzyme variant under these artificial conditions.

Discussion {#humu22946-sec-0100}
==========

Expanding the Phenotype of WS to Include Neuronal Migration Disorders {#humu22946-sec-0110}
---------------------------------------------------------------------

Brain imaging in proband 5 (Fig. [1](#humu22946-fig-0001){ref-type="fig"}G) was consistent with that reported on two prior occasions in different children with WS \[Freeman et al., [1999](#humu22946-bib-0007){ref-type="ref"}; Al‐Salem et al., [2013](#humu22946-bib-0001){ref-type="ref"}\]. In each previous case, and in our case, there was asymmetric perisylvian polymicrogyria that appeared more severe on the right side, as well as mildly enlarged lateral ventricles. The report by Freeman et al. ([1999](#humu22946-bib-0007){ref-type="ref"}) described pachygyria, but based on review of the published images (W. Dobyns), we believe the findings are more consistent with perisylvian polymicrogyria. The image shown in the report by Al‐Salem et al. ([2013](#humu22946-bib-0001){ref-type="ref"}) demonstrates enlarged extra‐axial fluid spaces over the brain, similar in appearance to the polymicrogyria observed among megalencephaly syndromes associated with PI3K‐AKT pathway mutations \[Mirzaa et al., [2012](#humu22946-bib-0026){ref-type="ref"}\]. However, neither hydrocephalus nor Chiari malformations were seen in these WS patients. Tatton‐Brown et al. ([2013](#humu22946-bib-0042){ref-type="ref"}) also reported a case with pachy‐ and polymicrogyria, but no images were published.

Our proband 5 has the recurrent p.(Arg684Cys) *de novo* mutation, the patient with polymicrogyria and WS described by Al‐Salem et al. ([2013](#humu22946-bib-0001){ref-type="ref"}) was shown to have a *de novo* p.(Glu745Lys) mutation, and the patient from Tatton‐Brown et al. ([2013](#humu22946-bib-0042){ref-type="ref"}) had an *EZH2* variant predicted to truncate the protein at position 732. The association of polymicrogyria with WS in four independent cases, two of which have molecular confirmation of *de novo* mutations in different exons of *EZH2* and another of which has a truncating variant in the last exon, strongly supports a causal association between *EZH2* mutations and neuronal migration defects in some patients with WS. EZH2 has been shown to control the decision between self‐renewal and differentiation in the cerebral cortex, and inhibition of PRC2 complex activity had been shown to shift the balance toward differentiation \[Pereira et al., [2010](#humu22946-bib-0031){ref-type="ref"}\]. Furthermore, EZH2 has also been shown to orchestrate neuronal migration in the cortico‐ponto‐cerebellar pathway in mice \[Di Meglio et al., [2013](#humu22946-bib-0005){ref-type="ref"}\]. The possibility that diminished PRC2 complex activity could lead to premature neuronal differentiation, possibly at ectopic sites along the normal migration pathway, offers a plausible explanation for the cortical patterning defects seen in patients with WS and pachy‐ or polymicrogyria.

Thus, in addition to their known risk for neoplastic disease, patients with WS should be considered to be at risk for neuronal migration disorders, and physicians should have a low threshold for ordering cranial imaging studies. Similarly, children with overgrowth and cerebral migration disorders could be tested for rare variants in *EZH2*, and physicians performing prenatal diagnosis in the context of a fetus with polymicrogyria should consider the possibility of WS.

Given the large number of individuals now being studied with high‐throughput next‐generation sequencing, rare variants in *EZH2* that are discovered through targeted sequencing panels, exome sequencing, or whole‐genome sequencing should be considered carefully in the context of clinical findings such as overgrowth phenotypes, cerebral malformations, and neoplastic disease. For highly heterogeneous disorders such as overgrowth syndromes, techniques such as exome sequencing are becoming cost‐effective for diagnosis at an early stage of the workup. An estimate of diagnostic costs incurred during the workup of proband 5 is presented in Supp. Table S6, for theoretical comparison to early exome sequencing (though in his particular case, *EZH2* was selected on a candidate gene basis).

WS Mutations and Neoplastic Disease {#humu22946-sec-0120}
-----------------------------------

With somatic mutations in *EZH2* having been associated to both gain and loss of histone methyltransferase function, it was important to investigate mutations found in WS patients who had also developed malignancies. To date, none of the three cases from our original report have been diagnosed with neoplastic disease. However, proband 4 had a nonmetastatic stage 4S neuroblastoma in his left adrenal gland. Our functional analysis of the EZH2 p.(Pro132Ser) mutant complex suggested a loss‐of‐function effect, consistent with a previous report of this variant in the context of myeloid disorders \[Guglielmelli et al., [2011](#humu22946-bib-0009){ref-type="ref"}\]. Proband 6 had a prenatal neuroblastoma in the right adrenal gland that was successfully removed surgically shortly after birth, and the EZH2 p.(Tyr133Cys) mutant complex also appeared to be loss‐of‐function in our assay. The other two mutant complexes containing mutations found in patients with malignancies, EZH2 p.(Arg682Thr), and p.(Glu745Lys) \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}\], also showed loss‐of‐function *in vitro*, suggesting that the mechanism driving cancer in WS patients resembles that of myeloid disorders and acute lymphoblastic leukemia rather than that of diffuse large B‐cell and non‐Hodgkin lymphomas. Furthermore, the p.(Arg684Cys) mutation reported in several independent cases \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}\] and identified in proband 5, which has not yet been associated with malignancy development in WS but appears to be a true recurrent mutation, had already been described as likely inactivating in myeloid disorders \[Ernst et al., [2010](#humu22946-bib-0006){ref-type="ref"}\]. Overall, all *de novo* WS‐associated *EZH2* mutations showed impaired histone methyltransferase activity *in vitro*, particularly with reduced ability to monomethylate H3K27 (Supp. Fig. S1 and Supp. Table S5D). Impaired histone methyltransferase activity had previously been observed among *NSD1* mutations causing Sotos syndrome (MIM \#117550) \[Qiao et al., [2011](#humu22946-bib-0033){ref-type="ref"}; Kudithipudi et al., [2014](#humu22946-bib-0017){ref-type="ref"}\], which is another overgrowth syndrome that shares significant phenotypic overlap with WS \[Tatton‐Brown and Rahman, [2013](#humu22946-bib-0043){ref-type="ref"}\]. Based on these results, we suggest that EZH2 inhibitors currently being developed against various cancers \[Knutson et al., [2012](#humu22946-bib-0015){ref-type="ref"}; McCabe et al., [2012b](#humu22946-bib-0025){ref-type="ref"}; Qi et al., [2012](#humu22946-bib-0032){ref-type="ref"}; Knutson et al., 2013\] may not be of specific benefit in WS. Importantly, we did not assay PRC2‐independent functions of EZH2, so additional complexity in the functional effects of disease‐associated EZH2 mutations remains to be unraveled.

Methyltransferase Activity of p.(Asp185His) {#humu22946-sec-0130}
-------------------------------------------

We identified the p.(Asp185His) variant in five individuals who were referred for WS‐like features, including macrocephaly. This variant has been found in multiple healthy controls, as well as among individuals affected with generalized overgrowth or acute leukemia \[Tatton‐Brown et al., [2011](#humu22946-bib-0041){ref-type="ref"}; Grossmann et al., [2012](#humu22946-bib-0010){ref-type="ref"}\]. Importantly, recent genome‐wide association studies for human height and for infant head circumference have not identified this variant as a risk factor for either of these quantitative traits \[Taal et al., [2012](#humu22946-bib-0039){ref-type="ref"}; Wood et al., [2014](#humu22946-bib-0049){ref-type="ref"}\]. Thus, population genetic evidence supports the classification of the p.(Asp185His) variant as a common, benign SNP (single‐nucleotide polymorphism). In this context, the fact that our functional work suggests impaired histone methyltransferase activity for this mutant is notable. Based on careful repetition of our assays with different lot numbers of the WT protein and under varied conditions (Fig. [2](#humu22946-fig-0002){ref-type="fig"}; Supp. Figs. S2 and S3), we do believe our *in vitro* results to be reproducible. Given the reproducibility of our assay in our hands and the use of a similar assay by multiple other groups, we do not believe the low methyltransferase activity exhibited by the p.(Asp185His) protein variant in this assay is indicative of experimental error. Rather, we believe that our results reflect the true activity of this variant under this select set of experimental conditions. Nevertheless, given the lack of a specific phenotype for p.(Asp185His) carriers, these *in vitro* results may not reflect its true activity *in vivo*. On this basis, we must conclude that this particular *in vitro* assay cannot be used in isolation to assess the potential pathogenicity of novel *EZH2* variants. Instead, pathogenicity should be assessed based on the sum total of available evidence from family‐specific cosegregation with disease phenotypes, population genetics, and, where available, other orthogonal lines of functional evidence. The possibility of "pseudodeficiency alleles" is an uncommon but known phenomenon whereby some protein variants manifest impaired activity by *in vitro* assays but have no demonstrable phenotypic effects *in vivo* \[Coulter‐Mackie and Gagnier, [2003](#humu22946-bib-0004){ref-type="ref"}; Yasuda et al., [2003](#humu22946-bib-0052){ref-type="ref"}; Tomatsu et al., [2009](#humu22946-bib-0045){ref-type="ref"}\]. To understand the discrepancy between the predicted (normal) activity of a common protein variant and its observed (deficient) activity more fully would require more definitive studies such as determination of the binding constant (*K* ~m~) for substrates, assays over the linear portion of the product versus time curve, and careful substudies of the different enzymatic steps for a variety of different rare and common protein variants.

Histone Methyltransferase Activity Does Not Correlate with Phenotypic Severity {#humu22946-sec-0140}
------------------------------------------------------------------------------

We chose to assay EZH2 protein variants that represented a wide variety of WS phenotypes. We had hypothesized that more severe clinical features of WS (such as cerebral migration defects, or the development of malignancy) might be associated with mutations in specific protein domains that were in turn associated with more striking alterations of histone methyltransferase activity. However, we observed no clear correlation between these parameters. We also observed no correlation between clinical severity and profiles of substrate specificity (Supp. Fig. S1). Our results are consistent with Guglielmelli et al. ([2011](#humu22946-bib-0009){ref-type="ref"}) who observed no correlation between *EZH2* mutational status and hematologic or clinical parameters in patients with myelofibrosis. This lack of phenotype/genotype correlation suggests that factors apart from histone methyltransferase function (such as the presence of modifier genes, other epigenetic modifications such as H3K4 methylation, or stochastic modifiers) might explain the phenotypic differences observed in WS patients. Activity of accessory proteins that are absent from our *in vitro* assay might also change the conformation of the PRC2 complex and influence the resulting phenotype. Such factors include the presence of PHF1 \[Sarma et al., [2008](#humu22946-bib-0035){ref-type="ref"}\], the activity of NF‐kB \[Lee et al., [2011](#humu22946-bib-0019){ref-type="ref"}\], WNT \[Wang et al., [2010](#humu22946-bib-0047){ref-type="ref"}\], or Akt, that modifies EZH2 post‐translationally \[Cha et al., [2005](#humu22946-bib-0003){ref-type="ref"}\]. Alternatively, the activity of WS mutants on nonhistone substrates, such as STAT3 \[Kim et al., [2013b](#humu22946-bib-0014){ref-type="ref"}\] or JARID2 \[Sanulli et al., [2015](#humu22946-bib-0034){ref-type="ref"}\], may be a more important determinant of the ultimate phenotype of WS patients.
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